Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

1.080 -0.010 (-0.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Adaptimmune Ther ADR

< Previous 1 2 3 Next >
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
Recap: Adaptimmune Therapeutics Q1 Earnings
 
Via Benzinga
Earnings Preview For Adaptimmune Therapeutics
 
Via Benzinga
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
The company bulks up its pipeline by regaining the rights to two of its clinical programs. 
Via The Motley Fool
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
 
Via Benzinga
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
 
Via Benzinga
Adaptimmune Therapeutics's Earnings Outlook
 
Via Benzinga
Expert Ratings for Adaptimmune Therapeutics
 
Via Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to... 
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
Positive trial data is powering the biotech's stock higher today. 
Via The Motley Fool
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Credit Suisse, Autodesk And Other Big Losers From Wednesday
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers DBV Technologies (NASDAQ:DBVT) stock increased by 18.7% to $1.9 during Tuesday's after-market session. The company's market cap stands at $356.7 million. 
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
 
Via Benzinga
Domino's Pizza To $385? Plus This Analyst Cuts Price Target On Adaptimmune Therapeutics By Around 79%
UBS cut the price target on Domino's Pizza, Inc. (NYSE: DPZ) from $430 to $385. Domino's shares rose 4% to $329.11 on Tuesday. 
Via Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
 
Via Benzinga
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Adaptimmune Therapeutics: Q2 Earnings Insights
  Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.